




CERTIFICATE OF VERIFICATION

I, Naoko AZUMA, a national of Japan, c/o SAEKI & PARTNERS of 9th Floor, Taka-ai Building, 15-2, Nihonbashi 3-chome, Chuo-ku, Tokyo, JAPAN

do hereby solemnly and sincerely declare:

- 1) THAT I am well acquainted with the Japanese language and the English language, and
- 2) THAT the attached is a true, accurate and faithful translation into the English language made by me of Japanese Patent Application No. 304085/1998 filed with the Japanese Patent Office on October 26, 1998.

Signed this 12th day of November, 2002.


Naoko AZUMA

RECEIVED

JAN 08 2003

TECH CENTER 1600/2900

[Document Name] Application for Patent

[Reference Number] PA907483

[Date] October 26, 1998

[Addressed to] Commissioner of Patent Office,
Mr. Takeshi ISAYAMA

[IPC] C12Q

C07K

[Title of Invention]

A NOVEL I κ B KINASE (IKK-i) AND GENE ENCODING THE SAME

[Number(s) of Claims] 6

[Inventor]

[Domicile] 6-17-18-202, Onohara-higashi, Minoo-shi,
Osaka-fu

[Name] Shizuo AKIRA

[Inventor]

[Domicile] 4-18, Toriishi 5-chome, Takaishi-shi,
Osaka-fu

[Name] Takahiro SHIMADA

[Applicant]

[Identification Number] 396020800

[Name] Japan science and Technology Corporation

[Representative] Moritaka NAKAMURA, President

[Attorney]

[Identification Number] 100102668

[Patent Attorney]

[Name] Norio SAEKI

[Phone Number] 03-5205-2521

[Indication of Fee]

[Method of Payment] Deposit

[Deposit Account] 039251

[Fee] ¥21,000

[List of Document(s)]

[Name of Document]	Specification	1
--------------------	---------------	---

[Name of Document]	Drawings	1
--------------------	----------	---

[Name of Document]	Abstract	1
--------------------	----------	---

[Document Name] Specification

[Title of Invention] A NOVEL I κ B KINASE (IKK-i) AND GENE ENCODING THE SAME

[Claims]

[Claim 1] A protein comprising an amino acid sequence represented by SEQ ID NO: 2 or SEQ ID NO: 4, or an amino acid sequence, in which one or more amino acids in the said amino acid sequence are deleted or replaced by other amino acids, and/or one or more other amino acids are added, and capable of activating transcription factor NF- κ B.

[Claim 2] The protein according to claim 1, which is serine/threonine kinase.

[Claim 3] A gene comprising base sequence coding the protein according to claim 1.

[Claim 4] The gene according to claim 3, wherein the base sequence comprises the base sequence represented by SEQ ID NO: 1 or SEQ ID NO: 3.

[Claim 5] A pharmaceutical composition comprising the protein according to claim 1 or 2 and a pharmaceutically acceptable carrier.

[Claim 6] The pharmaceutical composition according to claim 5, which acts on the immune response mechanism.

[Detailed Description of the Invention]

[0001]

[Technical Field of the Invention]

The present invention relates to a novel I κ B kinase, the gene for it and a pharmaceutical composition containing it. More particularly, the present invention pertains to a novel I κ B kinase, IKK-i, which is a novel serine/threonine kinase capable of activating transcription factor NF- κ B which regulates expression of various genes involved in immune response.

[0002]

[Prior Art]

Macrophages play an important role in biological defense mechanisms and are known to play major roles in functions such as phagocytosis. They are also involved in antigen presentation against bacterial infections and infiltration by malignant tumor. Further, macrophages are activated by lipopolysaccharide (LPS) and inflammatory cytokines, and they express various genes involved in the immune response. These include the major histocompatibility antigen, TNF- α (tumor necrosis factor- α), IL-1 β (interleukin-1 β), IL-6 (interleukin-6) and MIP-1 α/β (macrophage inflammatory protein-1 α/β).

[0003]

NF- κ B is a transcription factor which regulates the expression of various genes involved in the immune response. NF- κ B is known to be activated by LPS, TNF- α and IL-1 β , and to regulate transcription of genes of TNF- α , IL-1 β and I κ B- α , which have important roles in the immune response.

In order to identify a novel gene involved in the immune response, the inventors have performed subtractive hybridization between a (+)

group and a (-) group of LPS stimulation from the macrophage tumor strain, RAW 264.7. The gene obtained in this way, clone #2F9, was demonstrated to be a novel gene having homology with I κ B kinase- α , β (DiDonato, J.A., et al., Nature 1997, Aug. 7, 388 (6642), 548-554; Zandi, E. et al., Cell 1997, Oct. 17, 91(2), 243-252; Mercurio, F. et al., Science 1997, Oct. 31, 278 (5339), 860-866; Woronicz, J.D., et al., Science 1997, Oct. 31, 278 (5339), 866-869; Regnier, C.H., et al., Cell 1997, Jul. 25, 90(2), 373-383). This gene was identified recently and is known to activate NF- κ B. The inventors have given the name IKK-i (inducible-I κ B kinase) to the protein coded by this novel gene.

[0004]

[Problems to be Solved by the Invention]

The present invention provides a novel I κ B kinase, IKK-i, which is a novel serine/threonine kinase capable of activating transcription factor NF- κ B which regulates expression of various genes involved in immune response, and also the gene coding for the same and pharmaceutical composition containing the same.

The inventors have proved that IKK-i is a novel serine/threonine kinase which phosphorylates I κ B and activates NF- κ B, and whose expression is induced by various inflammatory cytokines.

[0005]

[Means for Solving the Problems]

The present invention relates to a protein having an amino acid sequence represented by SEQ ID NO: 2 or SEQ ID NO: 4, or an amino acid

sequence in which one or more amino acids in the said amino acid sequence is deleted or substituted by other amino acids and/or one or more other amino acid is added, and being able to activate the transcription factor NF- κ B. The protein of the present invention is a novel serine/threonine kinase.

[0006]

The present invention further relates to a gene having a base sequence which codes for the above mentioned novel protein. More particularly, the present invention pertains to a gene having a base sequence represented by SEQ ID NO: 1 or SEQ ID NO: 3.

The present invention further more relates to a pharmaceutical composition comprising the above mentioned protein and a pharmaceutically acceptable carrier thereof. The pharmaceutical composition of the present invention can activate the transcription factor NF- κ B and also acts on the immune response mechanism. Further, the pharmaceutical composition of the present invention is useful as a preventive or therapeutic agent against diseases involving I-TRAF or TRAF molecule.

[0007]

Firstly, cDNA cloning of IKK-i of the present invention is explained.

Using the suppression subtractive hybridization technique, a subtraction between a group with lipopolysaccharide (LPS) stimulation (+) and a group without LPS stimulation (-) was performed against RAW 264.7, a macrophage tumor strain. Subsequently, screening for the gene

induced by LPS stimulation was carried out. Seven new gene fragments, in addition to known genes such as MIP-1 α/β , G-CSF and TNF- α , were obtained.

[0008]

As the result of testing these fragments, only slight expression of clone #2F9 was observed in RAW 264.7 without stimulation, but the expression was markedly increased after 4 hours of the LPS stimulation (refer to Fig. 1). Fig. 1 shows the results of northern blotting analysis of the gene induced by lipopolysaccharide (LPS) stimulation of macrophage tumor strain RAW 264.7. Samples containing poly(A)⁺RNA 2 μ g before (-) or after (+) LPS (100 ng/ml) stimulation of RAW 264.7 were electrophoresed in 1% formamide-agarose and transferred to nylon membranes; they were then hybridized using a probe containing a cDNA fragment (2Fa) of IKK-i obtained by the subtraction. Fig. 1, lower photograph, shows that the amount of RNA is equivalent to the amount obtained by using G3PDH.

[0009]

As for the time course of expression of the mRNA, it started to increase 2 hours after from LPS stimulation, reached a peak value after 4 hours, and returned to the original level after 24 hours (refer to Fig. 2).

Fig. 2 shows that the results based on northern blotting analysis are similar to those in Fig. 1. Namely, RAW 264.7 was stimulated by 100 ng/ml LPS, the total RNA was extracted after the indicated number of hours in each lane, then 25 μ g of each sample was electrophoresed

in 1% formamide-agarose. The coding region of mouse IKK-i (mIKK-i) was used as a probe. In Fig. 2, the lower photograph shows that the amount of RNA is equivalent to that obtained by using G3PDH.

[0010]

A cDNA library was prepared using mRNA obtained by LPS stimulation of RAW 264.7 for 4 hours, and the full length of this gene was obtained by using fragment 2F9 as a probe. This gene codes for 718 amino acids in a 2154 bp open reading frame. As a result of a homology search, a human cDNA clone KIAA 0151, for which the base sequence was determined but the function was not known, showed the highest homology in the database. The homology was 82.3% in the amino acid level, consequently 2F9 was thought to be a counterpart of KIAA 0515 in the mouse.

The gene showing the second highest homology next to KIAA 0151 was I κ B kinase- α , β (IKK- α and IKK- β), which has been recently identified and demonstrated to phosphorylate I κ B- α and to activate NF- κ β . The homology of the kinase domain is 29.1% and 30.1% in the amino acid level, respectively.

[0011]

2F9 and KIAA have been confirmed to have a serine/threonine kinase domain in the N-terminal end, and a leucine-zipper domain in the center. Consequently, based on the similarities of the structures of IKK- α and IKK- β and the function of these molecules, for which more explanation will be given later, the inventors have named this novel kinase as inducible IKK (IKK-i).

[0012]

Comparisons of the amino acid sequences of human IKK-i and mouse IKK-i are shown in Fig. 3, and comparisons of the amino acid sequences of human IKK-i, human IKK- α and human IKK- β are shown in Fig. 4.

In Fig. 3, the identical sequences are enclosed by rectangles and the kinase domain is indicated by []. The leucine-zipper domain is indicated with an * mark below the domain.

In Fig. 4, the backgrounds of the identical sequences are colored with gray and the kinase domain is indicated by []. The activation loop is enclosed by a rectangle. The amino acid residues, which are thought to be important for kinase activity in the activation loop sequence, are indicated with an * mark. Under the helix loop - the helix structures of IKK- α and IKK- β are shown by underlining.

[0013]

The expression of IKK-i in various organs was analyzed by northern blotting. IKK- α and IKK- β were generally expressed in all tissues, on the contrary, mRNA of IKK-i was primarily expressed specifically in spleen, thymus, peripheral leukocytes, pancreas and placenta (refer to Fig. 5). Northern blotting analysis was performed by using multi-tissue northern blot membranes (Clontech), in which 2 μ g of poly (A)⁺RNA obtained from each of the indicated organs was placed in each lane shown in Fig. 5. A human IKK-i (hIKK-i) coding region was used as a probe.

[0014]

In order to determine from which cell population the expression of IKK-i found in the spleen originated, B-cells and T-cells were

isolated by using anti-B220 antibody. Before (-) and after (+) LPS stimulation of B-cells, and before (-) and after (+) phorbol ester and calcium ionophore stimulations of T-cells, the expression of IKK-i was analyzed by northern blotting. Though the expression was not able to be detected in B-cells without LPS stimulation, the expression was induced by LPS stimulation. Constitutive expression was observed in T-cells, but stimulation by phorbol ester and calcium ionophore reduced the expression (refer to Fig. 6).

[0015]

Fig. 6 shows the results of northern blotting analysis carried out as follows. B-cells and T-cells were isolated from the spleen cells collected from C57BL/6 using antibody (B220) in a high-gradient magnetic cell separation system MACS (Miltenyi Biotec, Berg.-Gladbach, Germany). B-cells were stimulated by 100 μ g/ml of LPS 100 and T-cells were stimulated by 10 μ M of ionomycin and 10 μ g/ml of PMA, each for 4 hours. Before and after the stimulation, the total RNA was extracted, and 20 μ g of each sample was electrophoresed using 1% formamide agarose, and analyzed by northern blotting in the same way as the case in Fig. 2. The coding region of mouse IKK-i (mIKK-i) was used as a probe. In Fig. 6, the lower photograph shows that the amount of RNA obtained is equivalent to that obtained by using G3PDH.

[0016]

The expression of IKK-i in mouse cell strains was analyzed before (-) or after (+) stimulation. The expression of IKK-i was induced in 5E3 (a natural killer cell clone) and M1 (a monocytic leukemia cell

line) by stimulation with LPS (refer to Fig. 7).

[0017]

The total amounts of RNA before (-) and after (+) 4 hours of stimulation with LPS (100 ng/ml) were extracted from tumor strain NIH 3T3 (a fibroblast cell line), EL-4 (thymoma cells), 5E3 (a natural killer cell clone), MOPC 315 (myeloma cells), BCL-1 (B cell leukemia cells) and M1 (a monocytic leukemia cell line) shown in each lane in Fig. 7, and analyzed by northern blottings using the same methods as shown in Fig. 2. The results are shown in Fig. 7. The coding region of mIKK-i was used as a probe. The lower part of Fig. 7 shows that the amount of RNA is equivalent to that obtained using the electrophoretic patterns of total RNA stained with ethidium bromide.

[0018]

A further enhancement effect of stimulation, other than the effect of LPS on expression of IKK-i, was examined. Peritoneal macrophages collected from C57BL/6 were stimulated by LPS, PMA, TNF- α , IL-1 β , IFN- γ or IL-6 for 4 hours, and the expression of IKK-i was observed. IKK-i was induced by TNF- α , IL-1 β , IFN- γ or IL-6 instead of LPS, but was not induced by PMA (refer to Fig. 8).

[0019]

Fig. 8 shows that the peritoneal macrophages collected from C57BL/6 were stimulated by LPS: 1 μ g/ml, PMA: 10 ng/ml, TNF- α : 100 ng/ml, IL-1 β : 100 ng/ml, IFN- γ : 250 U/ml or IL-6: 2000 U/ml as shown in the upper part of each lane in Fig. 8. Subsequently, the total RNA was extracted then analyzed by northern blottings in the same way as

shown in Fig. 2. The coding region of mIKK-i was used as a probe. The lower part of Fig. 8 shows that the amount of RNA obtained is equivalent.

[0020]

It has been proved by a reporter gene assay that enforced intracellular expression of IKK- α and IKK- β results in activating NF- κ B. Owing to the structural similarities of IKK-i to them, the possibility of activating NF- κ B might be expected. Consequently, the possibility of NF- κ B activity of IKK-i was examined by a reporter gene assay.

First, a construct (pEF-BOS-FLAG-WT-IKK-i), in which FLAG epitope was tagged onto the N-terminal of IKK-i and inserted into pEF-BOS expression vector, was prepared. Then, pEF-BOS-FLAG-IKK-i or control of a vector only were transiently cotransfected into the luciferase reporter construct of NF- κ B and 293T cells, and luciferase activities were assayed. As the result, it was demonstrated that IKK-i activated NF- κ B in an expression-dependent manner (refer to Fig. 9).

[0021]

Fig.9 shows the results of the luciferase activity assay. In these studies, 293T cells were transiently cotransfected with the reporter construct (pNF- κ B-Luc) in which luciferase gene was ligated with the NF- κ B consensus sequence, the construct (pEF-BOS-FLAG-WT-IKK-i) in which FLAG epitope was tagged onto the N-terminal of IKK-i gene and subcloned into pEF-BOS expression vector, or a control of vector only. The total amounts of DNA were regularized to 4 μ g by using a pEF-BOS vector. The amounts of transfected

pEF-BOS-FLAG-WT-IKK-i are shown in the lower part of the graph, and the lower part of Fig. 9 shows the amount of protein, which was determined by immunoblotting using anti-FLAG antibody (M2).

[0022]

IKK- α and IKK- β have been known to phosphorylate I κ B- α in vitro. It was analyzed by an in vitro kinase assay whether or not the IKK-i of the present invention was able to phosphorylate the serine residues at No. 32 and No. 36.

A mutant construct (pEF-BOS-FLAG-K38A-IKK-i), which was prepared by mutating the No. 38 lysine of pEF-BOS-FLAG-WT-IKK-i or IKK-i to alanine, was transiently transfected into the 298T-cells. The IKK-i protein or the K38A-IKK-i protein expressed after 24 hours was purified by immunoprecipitation with anti-FLAG antibody (M2) and was used for an in vitro kinase assay.

[0023]

GST-I κ B- α N protein (WT) which was prepared by removing the C-terminal from an ankyrin repeat of I κ B- α , or GST-I κ B- α N protein (AA) which was prepared by replacing both of the No. 32 and No. 36 serine residues of GST-I κ B- α N with alanine, was used as a substrate. A band of autophosphorylated IKK-i at about 80 kDa was observed in a lane of the BOS-FLAG-WT-IKK-i. Though IKK-i phosphorylated GST-I κ B- α N protein (WT), K38A-IKK-i did not phosphorylate GST-I κ B- α N protein (WT). Further, IKK-i did not phosphorylate GST-I κ B- α N protein (AA) (refer to Fig. 10).

[0024]

Fig. 10 shows the results of phosphorylation of I κ B- α by IKK-i in vitro. ApEF-BOS-MOCK, a pEF-BOS-FLAG-WT-IKK-i, or a mutant construct (pEF-BOS-FLAG-K38A-IKK-I) which was prepared by mutating the No. 38 lysine of pEF-BOS-FLAG-WT-IKK-i to alanine, was transiently transfected into the 298T-cells. The IKK-i protein or the K38A-IKK-i protein expressed after 24 hours was purified by anti-FLAG antibody (M2) using immunoprecipitation, and was used for an in vitro kinase assay. GST-I κ B- α N protein (WT) which was prepared by removing the C-terminal from an ankyrin repeat of I κ B- α , or GST-I κ B- α N protein (AA) which was prepared by replacing both of the No. 32 and No. 36 serine residues of GST-I κ B- α N with alanine, was expressed in E. coli and purified using glutathione Sepharose, and the resulting products were used as substrates. IKK-i or K38A-IKK-i as substrates and [γ -³²P]ATP were reacted at 30°C for 20 minutes. The reaction mixture was developed with SDS-PAGE and measured by autoradiography. Arrows point to the bands of autophosphorylation and GST-I κ B- α N. The molecular weight (kDa) is shown on the left side. The lower part of Fig. 10 shows the results of determination of the amount of protein by immunoblotting using anti-FLAG antibody (M2).

[0025]

As a result, it was elucidated that the IKK-i of the present invention phosphorylated a serine residue in the N-terminal of I κ B which played an important role in the activation of NF- κ B.

[0026]

The base sequences and amino acid sequences clarified as a result

of cDNA cloning of the IKK-i of the present invention are shown in the sequence listings. SEQ ID NO: 1 shows the base sequence for human IKK-i (hIKK-i) and SEQ ID NO: 2 shows the amino acid sequence for hIKK-i. SEQ ID NO: 3 shows the base sequence for mouse IKK-i (mIKK-i) and SEQ ID NO: 4 shows the amino acid sequence for mIKK-i.

[0027]

It was found that the IKK-i of the present invention was a novel serine/threonine kinase having a kinase domain in the N-terminal and a leucine-zipper domain in the center and the expression of its mRNA was induced by LPS stimulation of macrophages. The amino acid sequence of the IKK-i of the present invention showed high homologies with IKK- α and IKK- β , which phosphorylate I κ B and activate NF- κ B.

[0028]

The IKK-i of the present invention was expressed constitutively in the spleen, thymus and peripheral leukocytes, and was also expressed constitutively in T-cells in the spleen. The expression was enhanced by LPS stimulation of B-cells, peritoneal macrophages, natural killer cells, and a monocyte tumor strain, and was also enhanced by stimulation of peritoneal macrophages by TNF- α , IL-1 β , IFN- γ or IL-6. As a result of northern blotting analysis, it has been shown that expression of IKK-i is directed mainly to immune competent cells and cells involved in the inflammatory reaction, and IKK-i may be a molecule involved in the inflammatory reaction since it is enhanced by inflammatory stimulation.

[0029]

Activation ability of IKK-i for NF- κ B was analyzed by a reporter gene assay, and it was found that enforced expression of IKK-i in the 293T cells resulted in activating NF- κ B in a amount-of-protein-dependent manner. From the fact that IKK-i can phosphorylate a serine residue in the N-terminal of I κ B- α in a manner similar to the actions of IKK- α and IKK- β , as elucidated by an in vitro kinase assay, it is suggested that the activation ability for the NF- κ B observed in the reporter gene assay may be dependent on phosphorylation of the N-terminal of I κ B- α by IKK-i. IKK-i is a novel I κ B kinase, expression of which is induced by inflammatory stimulation of immune competent cells, and which activates NF- κ B.

[0030]

The IKK-i of the present invention may possibly have the ability to contribute to maintaining the activation of NF- κ B by stimulation of the LPS. This is suggested by the facts that the amount of expression increases 2 hours after from LPS stimulation and NF- κ B is activated in an expression-dependent manner. Since expression of IKK-i is directed to the immune competent cells as compared with IKK- α and IKK- β , the development of an inhibitor may possibly to be able to suppress the activation of NF- κ B specific to the immune system. Consequently, controlling IKK-i may contribute to the treatment of inflammatory diseases.

Also as previously explained, IKK-i is thought to be a very interesting molecule from a clinical standpoint.

[0031]

A pharmaceutical composition of the present invention is comprised of IKK-i and pharmaceutically acceptable carrier and can be administered in the form for administration. The dosage can be adjusted according to the situation of the patients.

The pharmaceutical composition of the present invention is effective for improvement of the immune response function and for treatments for inflammatory diseases.

[0032]

[Examples]

Following examples illustrate the present invention but are not construed as limiting the invention.

[0033]

Example 1 (cDNA cloning of mIKK-i)

Using the suppression subtractive hybridization technique, a subtraction between a group with 100 ng/ml of lipopolysaccharide (LPS) stimulation (+) and a group without the LPS stimulation (-) was performed against RAW 264.7, a macrophage tumor strain. Subsequently, screening for the gene induced by LPS stimulation was carried out. As a result, seven new gene fragments, in addition to known genes such as MIP-1 α/β , G-CSF and TNF- α , were obtained. Among seven novel genes, clone #2F9 was a gene fragment having 374 bp. In order to obtain full length of gene of the clone #2F9, a cDNA library was prepared using λ ZAP phage from mRNA obtained by LPS stimulation of RAW 264.7 for 4 hours. A fragment of 374 bp in the 2F9 was labeled with α - 32 P-dCTP by random labeling technique. A full length gene was obtained by screening of cDNA phage

library using the labeled 2F9 as a probe.

The full length of the clone thus obtained was 2910 bp. This gene codes for 718 amino acids in a 2154 bp open reading frame. The base sequence of this gene is shown in SEQ ID NO: 3. The amino acid sequence is shown in SEQ ID NO: 4.

[0034]

Example 2 (cDNA cloning of hIKK-i)

Based on the previously registered base sequence KIAA0151 in DDBJ, cDNA of human IKK-i was cloned by means of PCR using human placental cDNA library as a template. The sequences of the primer used for PCR were as follows:

5'-ctttgcctgactcagggcagctcagag-3', and

5'-atggtgcagaagagcagtgttggaatc-3'

This gene coded 716 amino acids in 2148 bp open reading frame. The base sequence of this gene is shown in SEQ ID NO:1. Amino acid sequence is also shown in SEQ ID NO: 2.

[0035]

Example 3 (Expression of clone #2F9 by LPS stimulation)

The northern blotting analysis of the gene induced by lipopolysaccharide (LPS) stimulation of macrophage tumor strain RAW 264.7 was performed. Samples containing 2 μ g of poly(A)⁺RNA before (-) or after (+) LPS (100 ng/ml) stimulation of RAW 264.7 were electrophoresed in 1% formamide-agarose and transferred to nylon membranes, then hybridized using a probe containing a cDNA fragment (2Fa) of IKK-i obtained by the subtraction.

Results are shown in Fig. 1. The lower photograph in Fig.1 shows that the amount of RNA is equivalent to the amount obtained by using G3PDH.

[0036]

Example 4 (Time-course of expression of clone #2F9 by LPS stimulation)

RAW 264.7 was stimulated by 100 ng/ml of LPS, the total RNA was extracted after 0.5, 2, 4, 8, 12 and 24 hours, respectively, then 25 μ g of each sample was electrophoresed in 1% formamide-agarose and northern blotting analysis was performed similar to those in example 3. The coding region of mouse IKK-i (mIKK-i) obtained in example 2 was used as a probe.

The results are shown in Fig. 2. The lower photograph in Fig. 2 shows that the amount of RNA is equivalent to that obtained by using G3PDH.

[0037]

Example 5 (Expression of IKK-i)

The expression of IKK-i in various organs was analyzed by northern blotting.

Northern blotting analysis was performed by using multi-tissue northern blot membranes (Clontech), in which 2 μ g of poly (A)⁺RNA obtained from each organ was placed. A human IKK-i (hIKK-i) coding region was used as a probe.

Results are shown in Fig. 5. In Fig. 5, an arrow indicates a position of IKK-i.

[0038]

Example 6 (Expression of IKK-i in spleen)

B-cells and T-cells were isolated from the spleen cells collected from C57BL/6 using antibody (B220) in a high-gradient magnetic cell separation system MACS (Miltenyi Biotec, Berg.-Gladbach, Germany). B-cells were stimulated by 100 μ g/ml of LPS and T-cells were stimulated by 10 μ M of ionomycin and 10 μ g/ml of PMA, each for 4 hours. Before and after the stimulation, the total RNA was extracted, and 20 μ g each of the samples were electrophoresed using 1% formamide agarose, and analyzed by northern blotting in the same way as the case in example 4. The coding region of mIKK-i was used as a probe.

Results are shown in Fig. 6. In Fig. 6, the lower photograph shows that the amount of RNA obtained is equivalent to that obtained by using G3PDH.

[0039]

Example 7 (Expression of IKK-i in cells of mice)

The total amounts of RNA before (-) and after (+) 4 hours of the stimulation with LPS (100 ng/ml) were extracted from tumor strain NIH 3T3 (a fibroblast cell line), EL-4 (thymoma cells), 5E3 (a natural killer cell clone), MOPC 315 (myeloma cells), BCL-1 (B cell leukemia cells) and M1 (a monocytic leukemia cell line) of mouse cell strains, and analyzed by northern blottings using the same methods as shown in example 4. The coding region of mIKK-i was used as a probe.

The results are shown in Fig. 7. The lower part of Fig. 7 shows that the amount of RNA is equivalent to that obtained using the electrophoretic patterns of total RNA stained with ethidium bromide.

[0040]

Example 8 (Expression of IKK-i in peritoneal macrophages)

The peritoneal macrophages collected from C57BL/6 were stimulated by LPS: 1 μ g/ml, PMA: 10 ng/ml, RNF- α : 100 ng/ml, IL-1 β : 100 ng/ml, IFN- γ : 250 U/ml or IL-6: 2000 U/ml. Subsequently, the total RNA was extracted then analyzed by northern blottings in the same way as in example 4. The coding region of mIKK-i was used as a probe.

Results are shown in Fig. 8. In Fig. 8, (-) indicates a case without stimulation.

The lower part of Fig. 8 shows that the amount of RNA obtained is equivalent to that obtained by using G3PPH.

[0041]

Example 9 (Construction of IKK-i expression vector)

FLAG epitope was tagged to the N-terminal end of IKK-i gene. Restriction enzyme SalI sites were constructed in the 5'- and 3'-ends of FLAG-hIKK-i fragment using primer sequences (1) and (2) of the following formulae by applying with PCR.

[0042]

(1) 5'-gggtcgacca ccatggacta caaggacgac gatgacaaga tgcagagcac agccaat-3'

(2) 5'-gtcgactcag accatcagga ggtgc-3'

The resulted sequence was subcloned into T-vector (p-GEM-T) (Promega), excised by using the restriction enzyme SalI, and subcloned into pEF-BOS expression vector to construct the expression vector pEF-BOS-FLAG-WT-IKK-i.

[0043]

Example 10 (Activation of NF- κ B by IKK-i)

The NF- κ B consensus reporter construct (pNF- κ B-Luc) (Stratagene Inc.) and IKK-i expression vector, 0 μ g (without addition), 0.3 μ g, 1.0 μ g and 3.0 μ g of pEF-BOS-FLAG-WT-IKK-i obtained in example 9 were added respectively to 3×10^5 cells of 293T cells, and transiently cotransfected by lipofection using Tran it LT-1 (Pan Vera Corp.). Then luciferase activity was assayed by using Dual Luciferase Reporter assay system (Promega Inc.). Vector only was added for the control group. The total amount of DNA was regularized to 4 μ g by using pEF-BOS vector.

Results are shown in Fig. 9. The lower part of Fig. 9 shows the amount of protein, which was determined by immunoblotting using anti-FLAG antibody (M2).

[0044]

Example 11 (Preparation of a mutant of IKK-i, in which No. 38 lysine is replaced by alanine)

The bases coding No. 38 lysine in IKK-i were replaced by the bases coding alanine and a gene of IKK-i mutant was prepared by means of point mutation technique. Transformer site directed mutagenesis kit (Clontech Inc.) was used for point mutation.

[0045]

Example 12 (Construction of expression vector of mutant of IKK-i)

The expression vector of the mutant, pEF-BOS-FLAG-K38A-IKK-i, was prepared by the same way as of in example 9 using the mutant gene

obtained in example 11.

[0046]

Example 13 [Preparation of GST-I κ B- α N protein (WT)]

A gene coding amino acids 1 - 72 in the amino acid sequence, in which the C-terminal part was split from ankyrin repeat in I κ B- α , was prepared and this was expressed in E. coli. The resulted product was purified by using glutathione Sepharose to obtain GST-I κ B- α N protein (WT). PGEX2T (Pharmacia Inc.), was used as the vector.

[0047]

Example 14 [Preparation of GST-I κ B- α N protein (AA)]

A gene, in which both of bases coding for the No. 32 and No. 36 serine residues of GST-I κ B- α N were replaced by the bases coding for alanine, was prepared. This was expressed in E. coli and purified using glutathione Sepharose to obtain GST-I κ B- α N protein (AA).

[0048]

Example 15 (Phosphorylation of serine residue of I κ B- α by IKK-i)

The pEF-BOS-MOCK, the pEF-BOS-FLAG-WT-IKK-i obtained in example 9, or the mutant construct (pEF-BOS-FLAG-K38A-IKK-i) obtained in example 12, was transiently transfected to 2×10^6 cells of 293T-cells on 10 cm dishes. After 24 hours, expressed IKK-i protein or K-38A-IKK-i protein was purified by means of immunoprecipitation and measured by in vitro kinase assay.

The GST-I κ B- α N protein (WT) obtained in example 14 or the protein (AA) obtained in example 15 was used as a substrate for the in vitro kinase assay.

IKK-i or K38A-IKK-i, substrates and [γ - 32 P]ATP were reacted at 30°C for 20 minutes. The reaction mixture was developed with SDS-PAGE and measured by autoradiography.

The results are shown in Fig. 10. In Fig. 10, the arrow pointing to a position of about 80 kDa shows a band of autophosphorylation and the arrow below it shows a band of GST-I κ B- α N. The molecular weight (kDa) is shown on the left side in Fig. 10. The lower part of Fig. 10 shows the results of determination of the amount of protein by immunoblotting using anti-FLAG antibody (M2).

As a results, K38A-IKK-i did not phosphorylate GST-I κ B- α N protein (WT) though IKK-i phosphorylated GST-I κ B- α N protein (WT). Further, IKK-i did not phosphorylate GST-I κ B- α N protein (AA).

[0049]

[Effect of the Invention]

The present invention provides a novel I κ B kinase, IKK-i, which is a novel serine/threonine kinase capable of activating transcription factor NF- κ B which regulates expression of various genes involved in immune response. The present invention also provides the gene coding for the same and a pharmaceutical composition containing the same. Since IKK-i of the present invention phosphorylates I κ B and activates NF- κ B, it is effective for improvement of the immune response function and for treatments for inflammatory diseases to regulate this gene.

[SEQUENCE LISTING]

<110> Japan Science And Technology Corporation

<120> Novel I κ B-kinase (IKK-i) and Gene encoding the same

<130> PA907483

<160> 4

<210> 1

<211> 2154

<212> DNA

<213> Human

<400> 1

agatgcagag cacagccaat tacctgtggc acacagatga cctgctgggg cagggggcca	60
ctgccagtgt gtacaaggcc cgcaacaaga aatccggaga gctggttgct gtgaaggtct	120
tcaacactac cagctacctg cggccccgcg aggtgcaggt gagggagttt gaggtcctgc	180
ggaagctgaa ccaccagaac atcgtcaagc tctttgcggt ggaggagacg ggcggaagcc	240
ggcagaaggt actggtgatg gagtactgct ccagtgggag cctgctgagt gtgctggaga	300
gccctgagaa tgcctttggg ctgcctgagg atgagttcct ggtggtgctg cgctgtgtgg	360
tggccggcat gaaccacctg cgggagaacg gcattgtgca tcgcgacatc aagccgggga	420
acatcatgcg cctcgtaggg gagggggggc agagcatcta caagctgaca gacttcggcg	480
ctgcccggga gctggatgat gatgagaagt tcgtctcggt ctatgggact gaggagtacc	540
tgcatcccga catgtatgag cgggcggtgc ttcgaaagcc ccagcaaaaa gcgttcgggg	600

tgactgtgga tctctggagc attggagtga ctttgtacca tgcagccact ggcagcctgc	660
ccttcacccc ctttgggtggg ccacggcgga acaaggagat catgtaccgg atcaccacag	720
agaagccggc tggggccatt gcaggtgccc agaggcgga gaacgggccc ctggagtgga	780
gctacacctt ccccatcacc tgccagctgt cactggggct gcagagccag ctggtgcca	840
tcctggccaa catcctggag gtggagcagg ccaagtgtg gggcttcgac cagttctttg	900
cggagaccag tgacatcctg cagcgagttg tcgtccatgt cttctccctg tcccaggcag	960
tcctgcacca catctatata catgcccaca acacgatage cattttccag gaggccgtgc	1020
acaagcagac cagtgtggcc ccccgacacc aggagtacct ctttgagggt cacctctgtg	1080
tcctcgagcc cagcgtctca gcacagcaca tcgccacac gacggcaagc agccccctga	1140
ccctcttcag cacagccatc cctaaggggc tggccttcag ggacctgct ctggacgtcc	1200
ccaagtctgt ccccaaagtg gacctgcagg cggattacaa cactgccaag ggcgtgttgg	1260
gcgccggcta ccaggccctg cggttggcac gggccctgct ggatgggcag gagctaattg	1320
ttcgggggct gcaactgggtc atggaggtgc tccaggccac atgcagacgg actctggaag	1380
tggcaaggac atccctcttc tacctcagca gcagcctggg aactgagagg ttcagcagcg	1440
tggctggaac gcctgagatc caggaactga aggcggctgc agaactgagg tccaggctgc	1500
ggactctage ggaggtcctc tccagatgct cccaaaatat cacggagacc caggagagcc	1560
tgagcagcct gaaccgggag ctggtgaaga gccgggatca ggtacatgag gacagaagca	1620
tccagcagat tcagtgtgtt ttggacaaga tgaacttcac ctacaaacag ttcaagaagt	1680
ctaggatgag gccagggctt ggctacaacg aggagcagat tcacaagctg gataaggtga	1740
atttcagtca tttagccaaa agactcctgc aggtgttcca ggaggagtgc gtgcagaagt	1800
atcaagcgtc cttagtcaca cacggcaaga ggatgagggt ggtgcacgag accaggaacc	1860
acctgcgcct ggttggctgt tctgtggctg cctgtaacac agaagcccag ggggtccagg	1920
agagtctcag caagctcctg gaagagctat ctcaccagct ctttcaggac cgagcaaagg	1980
gggctcagge ctgcgcgcct cccatagctc cttaccccag ccctacacga aaggacctgc	2040
ttctccacat gcaagagctc tgcgagggga tgaagctgct ggcatctgac ctccctggaca	2100

acaaccgcat catcgaacgg ctaaataagag tcccagcacc tcctgatgtc tgag 2154

<210> 2

<211> 716

<212> PRT

<213> Human

<400> 2

Met Gln Ser Thr Ala Asn Tyr Leu Trp His Thr Asp Asp Leu Leu	15
Gly Gln Gly Ala Thr Ala Ser Val Tyr Lys Ala Arg Asn Lys Lys	30
Ser Gly Glu Leu Val Ala Val Lys Val Phe Asn Thr Thr Ser Tyr	45
Leu Arg Pro Arg Glu Val Gln Val Arg Glu Phe Glu Val Leu Arg	60
Lys Leu Asn His Gln Asn Ile Val Lys Leu Phe Ala Val Glu Glu	75
Thr Gly Gly Ser Arg Gln Lys Val Leu Val Met Glu Tyr Cys Ser	90
Ser Gly Ser Leu Leu Ser Val Leu Glu Ser Pro Glu Asn Ala Phe	105
Gly Leu Pro Glu Asp Glu Phe Leu Val Val Leu Arg Cys Val Val	120
Ala Gly Met Asn His Leu Arg Glu Asn Gly Ile Val His Arg Asp	135
Ile Lys Pro Gly Asn Ile Met Arg Leu Val Gly Glu Glu Gly Gln	150
Ser Ile Tyr Lys Leu Thr Asp Phe Gly Ala Ala Arg Glu Leu Asp	165
Asp Asp Glu Lys Phe Val Ser Val Tyr Gly Thr Glu Glu Tyr Leu	180
His Pro Asp Met Tyr Glu Arg Ala Val Leu Arg Lys Pro Gln Gln	195
Lys Ala Phe Gly Val Thr Val Asp Leu Trp Ser Ile Gly Val Thr	210
Leu Tyr His Ala Ala Thr Gly Ser Leu Pro Phe Ile Pro Phe Gly	225
Gly Pro Arg Arg Asn Lys Glu Ile Met Tyr Arg Ile Thr Thr Glu	240
Lys Pro Ala Gly Ala Ile Ala Gly Ala Gln Arg Arg Glu Asn Gly	255
Pro Leu Glu Trp Ser Tyr Thr Leu Pro Ile Thr Cys Gln Leu Ser	270

Leu Gly Leu Gln Ser Gln Leu Val Pro Ile Leu Ala Asn Ile Leu	285
Glu Val Glu Gln Ala Lys Cys Trp Gly Phe Asp Gln Phe Phe Ala	300
Glu Thr Ser Asp Ile Leu Gln Arg Val Val Val His Val Phe Ser	315
Leu Ser Gln Ala Val Leu His His Ile Tyr Ile His Ala His Asn	330
Thr Ile Ala Ile Phe Gln Glu Ala Val His Lys Gln Thr Ser Val	345
Ala Pro Arg His Gln Glu Tyr Leu Phe Glu Gly His Leu Cys Val	360
Leu Glu Pro Ser Val Ser Ala Gln His Ile Ala His Thr Thr Ala	375
Ser Ser Pro Leu Thr Leu Phe Ser Thr Ala Ile Pro Lys Gly Leu	390
Ala Phe Arg Asp Pro Ala Leu Asp Val Pro Lys Phe Val Pro Lys	405
Val Asp Leu Gln Ala Asp Tyr Asn Thr Ala Lys Gly Val Leu Gly	420
Ala Gly Tyr Gln Ala Leu Arg Leu Ala Arg Ala Leu Leu Asp Gly	435
Gln Glu Leu Met Phe Arg Gly Leu His Trp Val Met Glu Val Leu	450
Gln Ala Thr Cys Arg Arg Thr Leu Glu Val Ala Arg Thr Ser Leu	465
Leu Tyr Leu Ser Ser Ser Leu Gly Thr Glu Arg Phe Ser Ser Val	480
Ala Gly Thr Pro Glu Ile Gln Glu Leu Lys Ala Ala Ala Glu Leu	495
Arg Ser Arg Leu Arg Thr Leu Ala Glu Val Leu Ser Arg Cys Ser	510
Gln Asn Ile Thr Glu Thr Gln Glu Ser Leu Ser Ser Leu Asn Arg	525
Glu Leu Val Lys Ser Arg Asp Gln Val His Glu Asp Arg Ser Ile	540
Gln Gln Ile Gln Cys Cys Leu Asp Lys Met Asn Phe Ile Tyr Lys	555
Gln Phe Lys Lys Ser Arg Met Arg Pro Gly Leu Gly Tyr Asn Glu	570
Glu Gln Ile His Lys Leu Asp Lys Val Asn Phe Ser His Leu Ala	585
Lys Arg Leu Leu Gln Val Phe Gln Glu Glu Cys Val Gln Lys Tyr	600
Gln Ala Ser Leu Val Thr His Gly Lys Arg Met Arg Val Val His	615
Glu Thr Arg Asn His Leu Arg Leu Val Gly Cys Ser Val Ala Ala	630
Cys Asn Thr Glu Ala Gln Gly Val Gln Glu Ser Leu Ser Lys Leu	645

Leu Glu Glu Leu Ser His Gln Leu Leu Gln Asp Arg Ala Lys Gly	660
Ala Gln Ala Ser Pro Pro Pro Ile Ala Pro Tyr Pro Ser Pro Thr	675
Arg Lys Asp Leu Leu Leu His Met Gln Glu Leu Cys Glu Gly Met	690
Lys Leu Leu Ala Ser Asp Leu Leu Asp Asn Asn Arg Ile Ile Glu	705
Arg Leu Asn Arg Val Pro Ala Pro Pro Asp Val ***	716

<210> 3

<211> 2910

<212> DNA

<213> Mouse

<400> 3

gaattcggca cgagaagata gccaaagcca ggagatgcag agtaccacta actacctgtg	60
gcatactgat gacctgctag ggcagggggc cactgccagt gtgtacaagg cccgaaacaa	120
gaaatccggg gaggtggttg ctgtaaaggt cttcaactca gccagctatc ggcgacctcc	180
tgaggttcag gtgagggagt ttgaggtcct gcggaggctg aatcaccaga acatcgtgaa	240
gctattcgca gtggaggaaa cgggaggcag ccggcagaag gtgctaata tggagtactg	300
ctccagtggg agcctgctga gcgtgctgga agaccctgag aacacgttcg ggctttctga	360
agaggagttc ctagtggtgc tgcgctgtgt ggtggctggc atgaaccacc tgcgggagaa	420
tggcattgtc catcgggaca tcaaacctgg gaacatcatg cgcttggtgg gcgaggaggg	480
gcagagcatc tataagctgt ctgacttcgg ggctgcccgc aagctggacg atgatgagaa	540
gtttgtttct gtctatggta cagaggaata cctgcaccct gacatgtatg agcgtgcagt	600
gctgcgcaaa cccagcaaa aggcatattg tgtgactgtg gatctctgga gtattggggt	660
gaccctgtac cagcgagcca caggcagtct gcccttcac cccttcggtg ggccccggcg	720
caacaaagag atcatgtaca gaatcaccac agagaagcca gccggggcca tttcagggac	780
tcagaagcag gaaaatggtc ccttgagtg gagctacagc ctcccatca cctgtagact	840

gtccatgggg ctgcagaacc agctggtgcc catcctggcc aacatcctgg aggtggaaga	900
ggataagtgc tggggctttg atcagttctt cgcggagacc agtgacattc tgcagcgaac	960
ggtcatccac gtcttttccc taccacaggc cgttttgcat catgtctaca tccacgcca	1020
caacacgatt gccatctttt tggaggctgt atatgagcag accaacgtga cccccaaca	1080
ccaggagtac ctcttcgagg gtcacccttg tgtccttgag ccaagcctct cagcccagca	1140
catgcccac acagctgcca gcagccctct aactctgttc agcatgtcca gcgacacacc	1200
taaggggctg gccttcaggg accctgctct ggatgtccca aagttcgtcc ctaaggttga	1260
cctacaggcc gattacagca cagctaaggg ggtgctgggc gctggctacc aggccctgtg	1320
gctggcgcg gtcctgctgg atggacaggc gttgatgctt cgggggttac attgggtcct	1380
ggaggtgctt caggacacgt gccagcagac actggaggtc acacggacag ccctcctcta	1440
cctcggcagc agcctgggca ctgaaagggt cagcagtgga tcggggatgc ctgacgtcca	1500
ggaacgaaag gaggccacag agctaagaac caggctgcag actctctcag agatcctgtc	1560
taaatgttcc cacaatgtca cagaaacca aaggagcctg agctgtctgg gtgaagagct	1620
tttaaagaac cgggaccaga ttcattgagga taacaaaagt atccagaaga ttcagtgttg	1680
tttgacaag atgcacttca tctacaaaca gttcaagaaa tccaggatga ggccagggt	1740
cagctacaat gaggagcaga tccacaagct ggataaggta aatttcagtc atctagccaa	1800
gaggctgctg caggtgttcc aggaggagtg tgtgcagacg tatcaggtgt cgctggtcac	1860
acacggcaag cggatgaggc aggtgcagag ggcccagaac cacctgcac tcattggcca	1920
ctctgtggcc acctgtaact cggaagcccg gggagcccag gagagtctga acaagatctt	1980
tgatcagctc cttctggaca gagcttccga acaggagct gaggtgtcac cgcaacctat	2040
ggctcctcat cccggccctg atccgaagga cctggctctt cacatgcagg agctttgtaa	2100
tgatatgaag ctattggcct ttgatctcca ggacaacaac cgactcatcg aacggttaca	2160
tagagttcca tcggcaccag atgtctgagc tccctggggg ttcacaaggc actcagaagc	2220
aatagaaaca ttcataattgt acccctacac tgtgagacca aattcagggc aagttctggt	2280
tccatctcac tagcctacct ccctcttggc cattggccat tggccaacaa actagcatta	2340

ctttgactgt cctcttggga agcagctagg acagggactc ctggccatcc caggcagtat	2400
ctacagaaga gaccatgcgg ctaccacagc cttatcaaga caccaagact gttcttcctt	2460
accaggctc tggaggtctg gtcttggaaa gaaaaggctc agccctctca cgctttgcac	2520
ttcccaggac cagcaggcat ctctgtggc ttctcctgcc tctccagggt gctggatcag	2580
aatgcttatt cttcgttggt tcctgtgctg tttcctgagt gtcccatcc cctggcctca	2640
ggcaaccac aaacggcccc tctgtgcttg gtctagatgc acctgcattt gagaaagtgg	2700
gtggttgagg ctaactgctg gtgctttgag gattctcctt gacctttctt ccgaggaacg	2760
cttggttcta agaaacagct ggtcagtatc aaccacagcc atgctaactg gacagatgtt	2820
ggaacccaaa gtcctaagga gagagcaggc ctgcacctc agacatggaa taaatacatc	2880
gccttttctg tttaaaaaaaa aaaaaaaaaa	2910

<210> 4

<211> 717

<212> PRT

<213> Mouse

Met Gln Ser Thr Thr Asn Tyr Leu Trp His Thr Asp Asp Leu Leu	15
Gly Gln Gly Ala Thr Ala Ser Val Tyr Lys Ala Arg Asn Lys Lys	30
Ser Gly Glu Val Val Ala Val Lys Val Phe Asn Ser Ala Ser Tyr	45
Arg Arg Pro Pro Glu Val Gln Val Arg Glu Phe Glu Val Leu Arg	60
Arg Leu Asn His Gln Asn Ile Val Lys Leu Phe Ala Val Glu Glu	75
Thr Gly Gly Ser Arg Gln Lys Val Leu Ile Met Glu Tyr Cys Ser	90
Ser Gly Ser Leu Leu Ser Val Leu Glu Asp Pro Glu Asn Thr Phe	105
Gly Leu Ser Glu Glu Glu Phe Leu Val Val Leu Arg Cys Val Val	120
Ala Gly Met Asn His Leu Arg Glu Asn Gly Ile Val His Arg Asp	135
Ile Lys Pro Gly Asn Ile Met Arg Leu Val Gly Glu Glu Gly Gln	150

Ser Ile Tyr Lys Leu Ser Asp Phe Gly Ala Ala Arg Lys Leu Asp	165
Asp Asp Glu Lys Phe Val Ser Val Tyr Gly Thr Glu Glu Tyr Leu	180
His Pro Asp Met Tyr Glu Arg Ala Val Leu Arg Lys Pro Gln Gln	195
Lys Ala Phe Gly Val Thr Val Asp Leu Trp Ser Ile Gly Val Thr	210
Leu Tyr His Ala Ala Thr Gly Ser Leu Pro Phe Ile Pro Phe Gly	225
Gly Pro Arg Arg Asn Lys Glu Ile Met Tyr Arg Ile Thr Thr Glu	240
Lys Pro Ala Gly Ala Ile Ser Gly Thr Gln Lys Gln Glu Asn Gly	255
Pro Leu Glu Trp Ser Tyr Ser Leu Pro Ile Thr Cys Arg Leu Ser	270
Met Gly Leu Gln Asn Gln Leu Val Pro Ile Leu Ala Asn Ile Leu	285
Glu Val Glu Glu Asp Lys Cys Trp Gly Phe Asp Gln Phe Phe Ala	300
Glu Thr Ser Asp Ile Leu Gln Arg Thr Val Ile His Val Phe Ser	315
Leu Pro Gln Ala Val Leu His His Val Tyr Ile His Ala His Asn	330
Thr Ile Ala Ile Phe Leu Glu Ala Val Tyr Glu Gln Thr Asn Val	345
Thr Pro Lys His Gln Glu Tyr Leu Phe Glu Gly His Pro Cys Val	360
Leu Glu Pro Ser Leu Ser Ala Gln His Ile Ala His Thr Ala Ala	375
Ser Ser Pro Leu Thr Leu Phe Ser Met Ser Ser Asp Thr Pro Lys	390
Gly Leu Ala Phe Arg Asp Pro Ala Leu Asp Val Pro Lys Phe Val	405
Pro Lys Val Asp Leu Gln Ala Asp Tyr Ser Thr Ala Lys Gly Val	420
Leu Gly Ala Gly Tyr Gln Ala Leu Trp Leu Ala Arg Val Leu Leu	435
Asp Gly Gln Ala Leu Met Leu Arg Gly Leu His Trp Val Leu Glu	450
Val Leu Gln Asp Thr Cys Gln Gln Thr Leu Glu Val Thr Arg Thr	465
Ala Leu Leu Tyr Leu Gly Ser Ser Leu Gly Thr Glu Arg Phe Ser	480
Ser Gly Ser Gly Met Pro Asp Val Gln Glu Arg Lys Glu Ala Thr	495
Glu Leu Arg Thr Arg Leu Gln Thr Leu Ser Glu Ile Leu Ser Lys	510
Cys Ser His Asn Val Thr Glu Thr Gln Arg Ser Leu Ser Cys Leu	525

Gly Glu Glu Leu Leu Lys Asn Arg Asp Gln Ile His Glu Asp Asn	540
Lys Ser Ile Gln Lys Ile Gln Cys Cys Leu Asp Lys Met His Phe	555
Ile Tyr Lys Gln Phe Lys Lys Ser Arg Met Arg Pro Gly Leu Ser	570
Tyr Asn Glu Glu Gln Ile His Lys Leu Asp Lys Val Asn Phe Ser	585
His Leu Ala Lys Arg Leu Leu Gln Val Phe Gln Glu Glu Cys Val	600
Gln Thr Tyr Gln Val Ser Leu Val Thr His Gly Lys Arg Met Arg	615
Gln Val Gln Arg Ala Gln Asn His Leu His Leu Ile Gly His Ser	630
Val Ala Thr Cys Asn Ser Glu Ala Arg Gly Ala Gln Glu Ser Leu	645
Asn Lys Ile Phe Asp Gln Leu Leu Leu Asp Arg Ala Ser Glu Gln	660
Gly Ala Glu Val Ser Pro Gln Pro Met Ala Pro His Pro Gly Pro	675
Asp Pro Lys Asp Leu Val Phe His Met Gln Glu Leu Cys Asn Asp	690
Met Lys Leu Leu Ala Phe Asp Leu Gln Asp Asn Asn Arg Leu Ile	705
Glu Arg Leu His Arg Val Pro Ser Ala Pro Asp Val ***	717

[Brief Description of Drawings]

[Fig.1]

Fig. 1 is a drawing replaced by a photograph showing the results of northern blotting analysis, in which the induction of expression of mRNA of IKK-i before stimulation (-) or after stimulation (+) by LPS is shown. The lower photograph shows the results obtained using G3PDH.

[Fig.2]

Fig. 2 is a drawing replaced by a photograph showing the results of northern blotting analysis, in which expression of mRNA of IKK-i after LPS stimulation is shown in a time-dependent manner. The lower photograph shows the results obtained using G3PDH.

[Fig.3]

Fig. 3 shows a comparison of the amino acid sequences of human IKK-i and mouse IKK-i. In the figure, the part enclosed by a rectangle shows an identical sequence; a part [] shows a kinase domain; and * shows a leucine-zipper domain.

[Fig.4]

Fig. 4 shows a comparison of the amino acid sequences of IKK-i, IKK- α and IKK- β . The parts colored with a gray backgrounds in the figure show identical sequences; the part [] shows a kinase domain; the part enclosed by a rectangle shows an activation loop; and * mark shows an amino acid residue which may be important for kinase activity.

[Fig.5]

Fig. 5 is a drawing replaced by a photograph showing the expression

of IKK-i in various organs based on northern blotting analysis.

[Fig.6]

Fig. 6 is a drawing replaced by a photograph showing the expression of IKK-i in B cells and T cells based on northern blotting analysis. The lower photograph shows result of using G3PDH.

[Fig.7]

Fig. 7 is a drawing replaced by a photograph showing the expression of IKK-i in a mouse tumor strain based on northern blotting analysis. The lower photograph shows total RNA stained with ethidium bromide.

[Fig.8]

Fig. 8 shows a drawing replaced by a photograph showing the induction of IKK-i in mouse peritoneal macrophages as a result of various stimulations based on northern blotting analysis. The lower photograph shows the result obtained using G3PDH.

[Fig.9]

Fig. 9 shows the results of activation of the NF- κ B reporter gene by enforced expression of IKK-i. The lower photograph is a drawing replaced by a photograph, showing the results of an evaluation of the amount of protein. These results were obtained by immunoblotting using anti-FLAG antibody (M2).

[Fig.10]

Fig. 10 is a drawing replaced by a photograph showing the results of phosphorylation of I κ B- α by IKK-i in vitro. The lower photograph shows the results of evaluation of the amount of protein based on the results of immunoblotting using anti-FLAG antibody (M2).




[Document Name]

Drawings

1/10

[Fig.1]

LPS stimulation \pm



G3PDH




[Fig.2]

0 0.5 2 4 8 12 24 h



IKK- β



G3PDH



[Fig. 3]

hIKK-i	1: MQST	ANYI	WHTDDLLGQGATASVYKARNKKSGE	LVAVKVFNTT	SYLRRP	REVVQVREFEVLRR	LNHNQNI VKLFAVEE	75				
mIKK-i	1: MQST	TNYI	WHTDDLLGQGATASVYKARNKKSGE	VVAVKVFNSA	SYRRP	PEVVQVREFEVLRR	LNHNQNI VKLFAVEE	75				
hIKK-i	76: TGGSRQKVL	V	MEYCSSGSLLSVLES	PENAFGLP	PE	EFVLVLRVCVAGMNNHLRENGIVHRDIKPGNIMRLVGEEGQ	150					
mIKK-i	76: TGGSRQKVL	I	MEYCSSGSLLSVLED	PENTFGLS	EE	EFVLVLRVCVAGMNNHLRENGIVHRDIKPGNIMRLVGEEGQ	150					
hIKK-i	151: SIYKL	TDFGAARE	LDDEKXFSVYGTTEEYHLHPD	MYERAVLRKPQKAF	GVTV	VDLWSIGVTLYHAAATGSLPFI	225					
mIKK-i	151: SIYKL	SDFGAARK	LDDEKXFSVYGTTEEYHLHPD	MYERAVLRKPQKAF	GVTV	VDLWSIGVTLYHAAATGSLPFI	225					
hIKK-i	226: GPRRNKEIMYRIT	TEKPA	GAIA	GAARR	ENGPLEWSY	TLPITC	QLSLGLQS	300				
mIKK-i	226: GPRRNKEIMYRIT	TEKPA	GAIS	GAARR	ENGPLEWSY	SLPITC	RLSMGLQN	300				
hIKK-i	301: ETSDILQRT	V	VHVFSLS	QAVLHH	IYIHAHNTIAIF	Q	EAHVHKT	375				
mIKK-i	301: ETSDILQRT	V	VHVFSLP	QAVLHHV	IYIHAHNTIAIF	LE	EAHYEQ	375				
hIKK-i	376: SSPLTLFS	-TA-	IPKGLAFRDPALDVPKFPKVDLQADYN	TAKGV	LGAGYQAL	RLAR	LLDGQ	448				
mIKK-i	376: SSPLTLFS	MSSDT	PKGLAFRDPALDVPKFPKVDLQADYS	TAKGV	LGAGYQAL	WLAR	LLDGQA	450				
hIKK-i	449: VLQA	TCRR	TLEVARTS	LLYL	SSSLGTERFSS	VAGT	PEIQEL	523				
mIKK-i	451: VLQD	TCQQ	TLEVTRTA	LLYL	GSSSLGTERFSS	GSGMP	DVQERKEA	525				
hIKK-i	524: NREL	V	KSRDQ	VHED-R	SIQ	IQCCCLDKMN	FIYKQFKKSRMRPGL	597				
mIKK-i	526: GEEL	L	KNRDQ	I	HEDNKS	SIQ	IQCCCLDKMH	600				
hIKK-i	598: QKYQA	SLVTHGKRM	R	V	HE	TRNHLR	V	EC	672			
mIKK-i	601: QTYQ	V	SLVTHGKRM	R	V	Q	RAQNHLH	L	IGH	673		
hIKK-i	673: SP	TRKDL	LLHMQEL	CEG	MKLLAS	DL	DNNRI	TERLN	RVP	AP	PDV	
mIKK-i	674: GP	DPKDL	V	FMQEL	CND	MKLLAF	DL	DNNRL	IERLH	RVP	SA	PDV

[Fig. 4]

hikk-i 1 MQSTANYL-----WHTDDL EOCATASAKKAKKSCGLVAVKVFNTTSYLPRVQVR EFEVL KENHON IAKLFAVEET-----GGSRQKVLVMEYCS 90
hikk-β 1 MSWSPSTITQTCGEMKERRGICGSGNVRWHNQETGEOTAKOCROEISPRNBERMEL ELOMTRRLTHPNVVAARDVBEQMOMAPNDLPLEAMEYCO 100
hikk-α 1 MERPPGLRPGACAPWVRERLGGGRGNVCLYQHRELDLKIAKSCGL EISTKNERWCH ELOMCKENHANVWACDVEELNII I-HDVPRLEAMEYCS 99

hikk-i 91 SGLSVLES PENAFGLPEDEFVVRVRCVVAQNMHERENGIVHRDIKPGNMRIVGEGOSLYKLTDFGAARELDDDEKFFSVYVGTTEEYHEDMYERAVL 190
hikk-β 101 GGLRHYENQFENGCGGREGAETLSDIA SALTCHENRTHRDIKPENNY-LOQGEORLTHKHTDGLYAKEDPOGSUCHSTVGTIGYIFABEULE----- 195
hikk-α 100 GGDPRKLVK FENGCGGKESQLESLSGICGIRVTHENKTHRDIKPENNY-LOQVGCK I HKHTDGLYAKEDPOGSUCHSTVGTIGYIFABEULE----- 194

hikk-i 191 RKPQOKAFGVVVDLWSIGVTLVYHAATGSLPRIE-----FCGPRNKEIMYRITTEKPAIAA-GAORRENGPEWSYTLBITCQBSGLQSQLVPILAN 283
hikk-β 196 ----QOKVTVVVDYWSRGTLAECEITGPRPRPENWQVQNHKVRQSEVDVWSEDLNCTWKESSSYBYNNNSVLAERLEKWTQEMLMWHPRORCT- 290
hikk-α 195 ----NKPYTAJVDYWSRGTMVSECTAGTSEHHHLOFTWHEKIKKIDPKCUPACEMSCIEVRESHIPOPNSCSLIVEHMENTWLOLMNWDPOORGGP 290

hikk-i 284 I-LEVEQAKC WGFDOFPAETSDFORVWVWVLSQAVLHHIYIHAHTIAIFQEAHVHQMSVAPRHOEYEFEGHECVLEPSVSAOHTAHTTASSPLT- 380
hikk-β 291 -DPYGPNGC-----KALDDENKLVHNNMTVTGHTYPTVEDESQSKARTQODTGTPEEDOEHTQEAETIIPDKPATOCISDCKINEGHLD 383
hikk-α 291 VDLNLKQPRC-----VLMDBHNNKLVHNNMTSAKHSFLLPPDESEHSTOSRTEREIGINTCSOEUSSETGISIDRRKPAQCV-----LDGVRGCD 380


hikk-i 381 ----GSS-----TAIPKGLAFRDPALDVPKFFPKVDLQADYNTAKGLGAGYQALRLARA-----ELDGOELMFRGLHWV---MEVLOATCRRTELEVARTS 465
hikk-β 384 MDLVFEFONSKITVETQISPRQPESSCLQEPKRNIAFFQKRWGVQVWHSIQTKEPCNRQOGORAMNTHNNSCLSKMNMA SMQOLKAKK 483
hikk-α 381 SYMYEEDKSKVMEGPFASRLSDCINYLQDSKIDLEPIIQIRKVAEAVNVVSGIKEDYSRHFQGORAVMLSLERYNANHTKNTLISASQOLKAKK 480

hikk-i 466 LYLSSS--GTERFSSVAGTPEIQELKAAAEFRSRLRTLA EVLRSQSN--TETQESLSINRELKSRDQVHEDRSIQIQCCCLDKMNFIMQFK-KS 560
hikk-β 484 DEKTSIQIDLEKYSQTERF-----GHTSDKILAW-REMEQAVELGRENKVERMMALQTDVLDORSKMGKGGTLDDEEQARELMRRREK 578
hikk-α 481 EEFHKSIOIDLEKYSQMTY-----GASSEKMKAW-KEMEKAHYAEVGVGYLEDQIMSHAFMELOKSPYGRGGLMESFEORATIDMKOLKHR 575

hikk-i 592 RMRPGLGYNEEQIH-----KLDKNSHAK-----RLQVFOEECVQKYQASLVTHGKRMVVHETRN-----HERLVGCSVAACNTEAQGVQE 640
hikk-β 579 RBQRTGDSQEMVRLLOAIQSFEXKVRVITYQLSKTVVCKOKALEEHRK--MEEVVLMNDEKTVRLQEKROKELWNEKTAGSK-----VRG 667
hikk-α 576 SDH-SYSDSTEMVKIIVHTVQSDRVLKELECHESKLLGCKKIDILPRK--VEVALSNIKEADNTVMFMQCKROKEIWHLLKTAGTQSSARSL-----VGS 669

hikk-i 641 SLSKLEELSHQLQODRAKGAQASPPPIAPYSSTRK--DULLHMQEIEGEM--KILLASDLLDNNRTIERLNRVPAPPD-----V 716
hikk-β 668 PVSCSPDSMNASRSQGLMSQPSSTASNSLPEBAKSEEVAHNNIC-TLENAQODTVREDOQFTALDWSWLOTEEEHSCLEQAS 756
hikk-α 670 SEEGAVTPQTSAWLP-PTSAEHDHSLSCVVTPQDGETSAQMIEENLN-CLGHSTIHEANEEQGNMNMNDNSNI-----TE 745


[Fig. 5]







6/10

[Fig. 6]






[Fig. 7]




[Fig. 8]






[Fig. 9]

over expression of IKK-*i* activates NF- κ B





α -FLAG





[Fig.10]





[Document Name] ABSTRACT

[Subject]

Present invention is to provide a Novel I κ B kinase IKK-i which is a novel serine/threonine kinase capable of activating a transcription factor NF- κ B which inhibits the expression of various genes relating to immune response; a gene encoding the same; and medicinal compositions containing the same.

[Means for Solution]

Present Invention relates to a Novel I κ B kinase IKK-i which is a novel serine/threonine kinase capable of activating a transcription factor NF- κ B which inhibits the expression of various genes relating to immune response; a gene encoding the same; and medicinal compositions containing the same.

[Chosen Drawings] None